Patents by Inventor Esmerelda VAN DER HELM

Esmerelda VAN DER HELM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adenovirus based malaria vaccine encoding and displaying a malaria antigen
    Patent number: 10517938
    Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant adenovirus vectors. Described are capsid modified replication deficient adenovirus particle encoding and displaying circumsporozoite (CS) protein NANP-repeats (CSshort) from a malaria-causing parasite, preferably P. falciparum, via a minor capsid protein IX and encoding a heterologous protein as a transgene. In a particular embodiment, said replication incompetent vectors of rare serotypes such as human adenovirus 35 (HAdV35) and human adenovirus 26 (HAdV26) comprise nucleic acid encoding the CS protein, as a transgene, from a malaria-causing parasite and encoding and displaying the NANP-repeat from a malaria-causing parasite (1) directly fused to the protein IX, (2) fused to protein IX via a flexible linker or (3) an alpha-helical viral origin spacer SP1 to ensure both humoral and cellular responses against the selected antigens.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: December 31, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Jerôme H. H. V. Custers, Jort Vellinga, Marija Vujadinovic, Esmerelda Van Der Helm
  • AN IMPROVED ADENOVIRUS BASED MALARIA VACCINE ENCODING AND DISPLAYING A MALARIA ANTIGEN
    Publication number: 20190083597
    Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant adenovirus vectors. Described are capsid modified replication deficient adenovirus particle encoding and displaying circumsporozoite (CS) protein NANP-repeats (CSshort) from a malaria-causing parasite, preferably P. falciparum, via a minor capsid protein IX and encoding a heterologous protein as a transgene. In a particular embodiment, said replication incompetent vectors of rare serotypes such as human adenovirus 35 (HAdV35) and human adenovirus 26 (HAdV26) comprise nucleic acid encoding the CS protein, as a transgene, from a malaria-causing parasite and encoding and displaying the NANP-repeat from a malaria-causing parasite (1) directly fused to the protein IX, (2) fused to protein IX via a flexible linker or (3) an alpha-helical viral origin spacer SP1 to ensure both humoral and cellular responses against the selected antigens.
    Type: Application
    Filed: January 19, 2017
    Publication date: March 21, 2019
    Inventors: Jerôme H.H.V. CUSTERS, Jort VELLINGA, Marija VUJADINOVIC, Esmerelda VAN DER HELM